Abstract
Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3-centered diseases.
Original language | English |
---|---|
Pages (from-to) | 75-92 |
Number of pages | 18 |
Journal | Heart failure clinics |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan-2018 |
Keywords
- Galectin-3
- Heart failure
- Fibrosis
- Galectin-3 inhibitor
- Biomarker
- Prognosis
- PRESERVED EJECTION FRACTION
- MODIFIED CITRUS PECTIN
- PROGNOSTIC VALUE
- CARDIOVASCULAR-DISEASE
- MYOCARDIAL FIBROSIS
- RISK STRATIFICATION
- GENERAL-POPULATION
- PREDICTIVE-VALUE
- PERFORMANCE-CHARACTERISTICS
- SERIAL MEASUREMENTS